Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma 3Triple Negative Breast Neoplasms 2Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Glioma 1Fibrolamellar hepatocellular carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

durvalumab 8Bevacizumab 7tremelimumab 4lenvatinib 3atezolizumab 3Nivolumab 3Ipilimumab 3fludarabine 2Magnetic Resonance Imaging 2Hepatectomy 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2trastuzumab deruxtecan 1toripalimab 1ropidoxuridine 1poly ICLC 1pembrolizumab 1brodalumab 1Whole Genome Sequencing 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radionuclide Imaging 1Pregabalin 1Pluvicto 1Platinum 1Paclitaxel 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × poly ICLC × 90 days × Clear all
NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡